These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

344 related articles for article (PubMed ID: 24608088)

  • 1. Activating FLT3 mutants show distinct gain-of-function phenotypes in vitro and a characteristic signaling pathway profile associated with prognosis in acute myeloid leukemia.
    Janke H; Pastore F; Schumacher D; Herold T; Hopfner KP; Schneider S; Berdel WE; Büchner T; Woermann BJ; Subklewe M; Bohlander SK; Hiddemann W; Spiekermann K; Polzer H
    PLoS One; 2014; 9(3):e89560. PubMed ID: 24608088
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Internal tandem duplication mutations in the tyrosine kinase domain of FLT3 display a higher oncogenic potential than the activation loop D835Y mutation.
    Marhäll A; Heidel F; Fischer T; Rönnstrand L
    Ann Hematol; 2018 May; 97(5):773-780. PubMed ID: 29372308
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SRC is a signaling mediator in FLT3-ITD- but not in FLT3-TKD-positive AML.
    Leischner H; Albers C; Grundler R; Razumovskaya E; Spiekermann K; Bohlander S; Rönnstrand L; Götze K; Peschel C; Duyster J
    Blood; 2012 Apr; 119(17):4026-33. PubMed ID: 22411868
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FLT3-ITD and tyrosine kinase domain mutants induce 2 distinct phenotypes in a murine bone marrow transplantation model.
    Grundler R; Miething C; Thiede C; Peschel C; Duyster J
    Blood; 2005 Jun; 105(12):4792-9. PubMed ID: 15718420
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ponatinib may overcome resistance of FLT3-ITD harbouring additional point mutations, notably the previously refractory F691I mutation.
    Zirm E; Spies-Weisshart B; Heidel F; Schnetzke U; Böhmer FD; Hochhaus A; Fischer T; Scholl S
    Br J Haematol; 2012 May; 157(4):483-92. PubMed ID: 22409268
    [TBL] [Abstract][Full Text] [Related]  

  • 6. AML-associated Flt3 kinase domain mutations show signal transduction differences compared with Flt3 ITD mutations.
    Choudhary C; Schwäble J; Brandts C; Tickenbrock L; Sargin B; Kindler T; Fischer T; Berdel WE; Müller-Tidow C; Serve H
    Blood; 2005 Jul; 106(1):265-73. PubMed ID: 15769897
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reversal of acquired drug resistance in FLT3-mutated acute myeloid leukemia cells via distinct drug combination strategies.
    Zhang W; Gao C; Konopleva M; Chen Y; Jacamo RO; Borthakur G; Cortes JE; Ravandi F; Ramachandran A; Andreeff M
    Clin Cancer Res; 2014 May; 20(9):2363-74. PubMed ID: 24619500
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Point mutations in the juxtamembrane domain of FLT3 define a new class of activating mutations in AML.
    Reindl C; Bagrintseva K; Vempati S; Schnittger S; Ellwart JW; Wenig K; Hopfner KP; Hiddemann W; Spiekermann K
    Blood; 2006 May; 107(9):3700-7. PubMed ID: 16410449
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Overexpression and constitutive activation of FLT3 induces STAT5 activation in primary acute myeloid leukemia blast cells.
    Spiekermann K; Bagrintseva K; Schwab R; Schmieja K; Hiddemann W
    Clin Cancer Res; 2003 Jun; 9(6):2140-50. PubMed ID: 12796379
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FLT3 signals via the adapter protein Grb10 and overexpression of Grb10 leads to aberrant cell proliferation in acute myeloid leukemia.
    Kazi JU; Rönnstrand L
    Mol Oncol; 2013 Jun; 7(3):402-18. PubMed ID: 23246379
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [FMS-like tyrosine kinase 3 gene mutations in acute myeloid leukemia].
    Han YL; Zhang SJ; Qiao C; Dai D; Sun XM; Xu YL; Qian SX; Xu W; Wang JS; Li JY
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Oct; 17(5):1135-9. PubMed ID: 19840437
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A dual inhibitor overcomes drug-resistant FLT3-ITD acute myeloid leukemia.
    Wang P; Xiao X; Zhang Y; Zhang B; Li D; Liu M; Xie X; Liu C; Liu P; Ren R
    J Hematol Oncol; 2021 Jul; 14(1):105. PubMed ID: 34217323
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mutations in the tyrosine kinase domain of FLT3 define a new molecular mechanism of acquired drug resistance to PTK inhibitors in FLT3-ITD-transformed hematopoietic cells.
    Bagrintseva K; Schwab R; Kohl TM; Schnittger S; Eichenlaub S; Ellwart JW; Hiddemann W; Spiekermann K
    Blood; 2004 Mar; 103(6):2266-75. PubMed ID: 14604974
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FLT3-TKD mutation in childhood acute myeloid leukemia.
    Liang DC; Shih LY; Hung IJ; Yang CP; Chen SH; Jaing TH; Liu HC; Wang LY; Chang WH
    Leukemia; 2003 May; 17(5):883-6. PubMed ID: 12750701
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FLT3-ITD confers resistance to the PI3K/Akt pathway inhibitors by protecting the mTOR/4EBP1/Mcl-1 pathway through STAT5 activation in acute myeloid leukemia.
    Nogami A; Oshikawa G; Okada K; Fukutake S; Umezawa Y; Nagao T; Kurosu T; Miura O
    Oncotarget; 2015 Apr; 6(11):9189-205. PubMed ID: 25826077
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Clinical Characteristics and Prognostic Relevance of Co-Mutated Genes in Acute Myeloid Leukemia Patients with
    Chen Y; Xie YY; Fang Y; Hong M; Liu WJ; Zhou X; Zhang W; Shi JN; Qian SX
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Aug; 32(4):1032-1038. PubMed ID: 39192394
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Specific pattern of protein expression in acute myeloid leukemia harboring FLT3-ITD mutations.
    Scholl S; Melle C; Bleul A; Spies-Weisshart B; Kunert C; Höffken K; von Eggeling F
    Leuk Lymphoma; 2007 Dec; 48(12):2418-23. PubMed ID: 18067018
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lineage-specific STAT5 target gene activation in hematopoietic progenitor cells predicts the FLT3(+)-mediated leukemic phenotype.
    Müller TA; Grundler R; Istvanffy R; Rudelius M; Hennighausen L; Illert AL; Duyster J
    Leukemia; 2016 Aug; 30(8):1725-33. PubMed ID: 27046463
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Shikonin Exerts an Antileukemia Effect against FLT3-ITD Mutated Acute Myeloid Leukemia Cells via Targeting FLT3 and Its Downstream Pathways.
    Zhao MN; Su L; Song F; Wei ZF; Qin TX; Zhang YW; Li W; Gao SJ
    Acta Haematol; 2024; 147(3):310-324. PubMed ID: 37926079
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Detection of point mutation at second tyrosine kinase domain of FLT3 gene in acute myeloid leukemia].
    Wang LH; Wang M; Zhou CL; Chen S; Zhang XW; Xing HY; Wang JX
    Zhonghua Xue Ye Xue Za Zhi; 2005 Jun; 26(6):335-8. PubMed ID: 16185475
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.